RT Journal Article
SR Electronic
A1 Parry, Nicola
T1 No Survival Benefit When Adding Everolimus to Trastuzumab and Paclitaxel in Advanced HER2-Positive BC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 56
SP 11
OP 12
DO 10.1177/1559897715571071
UL http://mdc.sagepub.com/content/14/56/11.abstract
AB The BOLERO-1 phase 3 clinical trial demonstrated that adding everolimus to weekly trastuzumab and paclitaxel, as first-line therapy, did not improve progression-free survival in women with previously untreated human epidermal growth factor receptor-2-positive advanced breast cancer. PFS was increased by 7 months with everolimus therapy in the HR-negative subgroup; however, this did not cross the statistical significance threshold. Increased adverse events were also reported in the everolimus-treated group, as well as on treatment, AE-related deaths.